Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology

Decoding Your Scans: How HCC is Diagnosed Without a Biopsy

At a Glance

Hepatocellular carcinoma (HCC) can often be definitively diagnosed without a biopsy using advanced imaging like an Eovist-enhanced MRI. If a scan shows a unique vascular signature resulting in an LR-5 score on the LI-RADS scale, doctors can confidently confirm liver cancer and begin treatment.

Return to Home

Diagnosing liver cancer is unique. For many other types of cancer, a biopsy (taking a physical sample of the tissue with a needle) is a mandatory first step. However, for Hepatocellular Carcinoma (HCC), doctors can often make a “definite” diagnosis using only advanced imaging scans [1][2]. This is possible because HCC has a very specific way of “lighting up” on scans that other tumors do not share [3][4].

The Universal Language: LI-RADS

To make sure every radiologist and doctor is on the same page, they use a system called LI-RADS (Liver Imaging-Reporting and Data System) [5][6]. Think of LI-RADS as a high-tech grading scale from 1 to 5 that tells your doctor how likely a spot on your liver is to be cancer [5]:

  • LR-1: Definitely benign (not cancer).
  • LR-3: Intermediate probability (could be several things).
  • LR-5: Definitely HCC. This is the score that typically allows your team to move straight to treatment [3][7].
  • LR-M: Malignant, but maybe not HCC (could be a different type of liver cancer) [2][8].

Why You Might Not Need a Biopsy

If your scan is graded as LR-5, it means the tumor has a specific “vascular signature” [7][2]. This signature includes:

  1. Arterial Phase Hyperenhancement (APHE): The tumor “glows” brightly when contrast dye first enters the arteries [3][4].
  2. Washout: The tumor fades faster than the rest of the liver as the dye leaves [3][9].
  3. Capsule: The appearance of a “ring” or border around the tumor [3].

Because the specificity (accuracy) of an LR-5 score is so high, a biopsy is often seen as an unnecessary risk [7][10]. Biopsies carry a small risk of bleeding or “seeding” (accidentally spreading cancer cells along the needle’s path), so if the imaging is clear, doctors prefer to avoid them [11][12].

Advanced Diagnostic Tools

Your doctor may use specific “boosts” to get the clearest picture possible:

The Eovist-Enhanced MRI

Eovist (also called gadoxetate disodium) is a special type of contrast dye used during an MRI [13]. Unlike standard dyes that just flow through the blood, Eovist is actually taken up by healthy liver cells [14][15].

  • Because cancer cells are “broken,” they don’t take up the Eovist [14].
  • This makes the cancer cells look dark while the healthy liver looks bright, making it much easier to spot very small tumors (less than 2 cm) that a standard scan might miss [13][16][17].

The AFP Biomarker

Alpha-fetoprotein (AFP) is a protein often measured via a simple blood test [18]. While not everyone with HCC has high AFP levels, it serves two main purposes:

  • Supportive Evidence: A high AFP level combined with a suspicious scan helps confirm the diagnosis [18][19].
  • Tracking: If your AFP is high at diagnosis, doctors can use it as a “thermometer” later to see how well your treatment is working [18][20].

Summary of Diagnostic Features

Feature What It Means in Plain Language
LR-5 Score The “Gold Standard” imaging result; means the spot is definitely HCC [7].
Washout A key sign on a scan where the tumor loses its dye faster than healthy tissue [3].
Threshold Growth A tumor that is growing rapidly (e.g., 50% larger in 6 months) [21].
Hepatobiliary Phase The part of an Eovist MRI that makes small tumors “pop” against healthy liver [14].

By combining these scans and blood tests, your team can create a detailed map of your liver and choose the safest, most effective treatment path without ever needing to perform an invasive biopsy [1][22].

Common questions in this guide

What does an LR-5 score mean on my liver scan?
An LR-5 score on the LI-RADS scale means that a spot on your liver is definitively hepatocellular carcinoma (HCC). This specific score usually allows your medical team to confidently diagnose liver cancer and begin treatment without needing an invasive biopsy.
Why can liver cancer be diagnosed without a biopsy?
HCC has a unique way of lighting up and fading on advanced imaging scans, known as a vascular signature. When a scan shows this specific pattern, doctors can be highly confident it is HCC, allowing you to avoid the bleeding and seeding risks associated with a physical biopsy.
What is an Eovist-enhanced MRI used for?
Eovist is a special contrast dye used during an MRI that gets absorbed by healthy liver cells but not by cancer cells. This makes tumors appear dark against a bright, healthy liver, making it much easier for doctors to spot very small cancers.
What does the AFP blood test tell my doctor?
Alpha-fetoprotein (AFP) is a protein that can be measured in your blood. High AFP levels combined with a suspicious scan help confirm an HCC diagnosis, and your doctor can also use this biomarker test later to track how well your treatment is working.
What does washout mean on my imaging report?
Washout is a key sign on an imaging scan where a tumor loses the contrast dye faster than the surrounding healthy liver tissue. It is one of the specific vascular features radiologists look for to confirm a diagnosis of HCC.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my imaging report graded using the LI-RADS system, and if so, what was my specific score (e.g., LR-5)?
  2. 2.If I have an LR-5 score, are we confident enough to proceed with treatment without a biopsy?
  3. 3.Did my MRI use a hepatobiliary contrast agent like Eovist, and did that help clarify any smaller nodules?
  4. 4.How does my AFP (Alpha-fetoprotein) level correlate with what you see on the scans?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Lessons learnt from pathologic imaging correlation in the liver: an historical perspective.

    Purcell Y, Copin P, Paradis V, et al.

    The British journal of radiology 2019; (92(1097)):20180701 doi:10.1259/bjr.20180701.

    PMID: 30604641
  2. 2

    Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI.

    Liu X, Ni X, Li Y, et al.

    Frontiers in oncology 2022; (12()):934045 doi:10.3389/fonc.2022.934045.

    PMID: 35847955
  3. 3

    Liver Imaging Reporting and Data System (LI-RADS) v2018: Review of the CT/MRI Diagnostic Categories.

    Kanmaniraja D, Dellacerra G, Holder J, et al.

    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2021; (72(1)):142-149 doi:10.1177/0846537119888393.

    PMID: 32063008
  4. 4

    Imaging After Locoregional Therapy for Hepatocellular Carcinoma With Emphasis on LIRADS Treatment Response Assessment Criteria.

    Bajaj G, Sundaram K, Jambhekar K, Ram R

    Seminars in ultrasound, CT, and MR 2021; (42(4)):390-404 doi:10.1053/j.sult.2021.03.002.

    PMID: 34130851
  5. 5

    Diagnostic Performance of Liver Imaging Reporting and Data System Version 2017 Versus Version 2018 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Comparative Studies.

    Kim YY, Lee S, Shin J, et al.

    Journal of magnetic resonance imaging : JMRI 2021; (54(6)):1912-1919 doi:10.1002/jmri.27664.

    PMID: 33929784
  6. 6

    Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview.

    Liava C, Sinakos E, Papadopoulou E, et al.

    World journal of gastroenterology 2022; (28(32)):4540-4556 doi:10.3748/wjg.v28.i32.4540.

    PMID: 36157932
  7. 7

    CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.

    Lee S, Kim YY, Shin J, et al.

    Journal of the American College of Radiology : JACR 2020; (17(10)):1199-1206 doi:10.1016/j.jacr.2020.06.005.

    PMID: 32640250
  8. 8

    Characteristics and Early Recurrence of Hepatocellular Carcinomas Categorized as LR-M: Comparison with Those Categorized as LR-4 or 5.

    Shin J, Lee S, Kim SS, et al.

    Journal of magnetic resonance imaging : JMRI 2021; (54(5)):1446-1454 doi:10.1002/jmri.27650.

    PMID: 33891790
  9. 9

    Imaging-based diagnosis of hepatocellular carcinoma: Liver Imaging Reporting and Data System and beyond.

    Haghshomar M, Kierans AS, Kulik L, et al.

    The British journal of radiology 2025; (98(1173)):1344-1355 doi:10.1093/bjr/tqaf123.

    PMID: 40609019
  10. 10

    Cirrhosis and LI-RADS.

    Papadatos D, Fowler KJ, Kielar AZ, et al.

    Abdominal radiology (New York) 2018; (43(1)):26-40 doi:10.1007/s00261-017-1425-8.

    PMID: 29218367
  11. 11

    When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review.

    Russo FP, Imondi A, Lynch EN, Farinati F

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2018; (50(7)):640-646 doi:10.1016/j.dld.2018.03.014.

    PMID: 29636240
  12. 12

    HCC in the Era of Emerging MASH: The Role of Ultrasound in Surveillance and New Sonographic Features in Diagnosis.

    Giorgio A, De Luca M, Lombardi A, et al.

    Cancers 2025; (17(24)) doi:10.3390/cancers17244037.

    PMID: 41463285
  13. 13

    The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.

    Li J, Wang J, Lei L, et al.

    European radiology 2019; (29(12)):6519-6528 doi:10.1007/s00330-019-06294-6.

    PMID: 31250172
  14. 14

    OATP1B3 Expression in Hepatocellular Carcinoma Correlates with Intralesional Gd-EOB-DTPA Uptake and Signal Intensity on Gd-EOB-DTPA-Enhanced MRI.

    Zhou X, Long L, Mo Z, Li Y

    Cancer management and research 2021; (13()):1169-1177 doi:10.2147/CMAR.S292197.

    PMID: 33603462
  15. 15

    Characteristics of Hypovascular versus Hypervascular Well-Differentiated Hepatocellular Carcinoma Smaller Than 2 cm - Focus on Tumor Size, Markers and Imaging Detectability.

    Sugimoto K, Kim SR, Imoto S, et al.

    Digestive diseases (Basel, Switzerland) 2015; (33(6)):721-7 doi:10.1159/000439078.

    PMID: 26488580
  16. 16

    Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.

    Pan J, Li W, Gu L, et al.

    European radiology 2022; (32(11)):7883-7895 doi:10.1007/s00330-022-08826-z.

    PMID: 35579711
  17. 17

    Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis.

    Liu X, Jiang H, Chen J, et al.

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2017; (23(12)):1505-1518 doi:10.1002/lt.24867.

    PMID: 28886231
  18. 18

    Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus.

    Han D, Li Y, He X, et al.

    Quantitative imaging in medicine and surgery 2023; (13(10)):7156-7169 doi:10.21037/qims-23-396.

    PMID: 37869332
  19. 19

    Prospective Comparison of Gd-EOB-DTPA-Enhanced MRI with Dynamic CT for Detecting Recurrence of HCC after Radiofrequency Ablation.

    Imai Y, Katayama K, Hori M, et al.

    Liver cancer 2017; (6(4)):349-359 doi:10.1159/000481416.

    PMID: 29234638
  20. 20

    Predicting early recurrence in hepatocellular carcinoma after hepatectomy using GD-EOB-DTPA enhanced MRI-based model.

    Zeng H, Ma Z, Tao Y, et al.

    European journal of radiology 2025; (188()):112130 doi:10.1016/j.ejrad.2025.112130.

    PMID: 40305886
  21. 21

    Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.

    Choi SJ, Choi SH, Kim DW, et al.

    Journal of hepatology 2023; (78(3)):596-603 doi:10.1016/j.jhep.2022.11.006.

    PMID: 36402451
  22. 22

    LI-RADS LR-5 on contrast-enhanced ultrasonography has satisfactory diagnostic specificity for hepatocellular carcinoma: a systematic review and meta-analysis.

    Jin H, Cai Y, Zhang M, et al.

    Quantitative imaging in medicine and surgery 2023; (13(2)):957-969 doi:10.21037/qims-22-591.

    PMID: 36819240

This page explains HCC diagnostic imaging and LI-RADS terminology for educational purposes. Always consult your oncologist or hepatologist to interpret your specific scans and diagnosis.

Get notified when new evidence is published on Hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.